Global Bioabsorbable Stents Industry

NEW YORK, Aug. 1, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Bioabsorbable Stents Industry
http://www.reportlinker.com/p01171460/Global-Bioabsorbable-Stents-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment

This report analyzes the worldwide markets for Bioabsorbable Stents in Thousand Units.

The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2018.

The report profiles 16 companies including many key and niche players such as Abbott Laboratories, Amaranth Medical, Inc., Arterial Remodeling Technologies SA, BIOTRONIK SE & Co. KG, Elixir Medical Corporation, Kyoto Medical Planning Co., Ltd., and REVA Medical, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-2
Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Prelude II-1
Evolution of Coronory Stents II-1
Current Global Coronory Stent Scenario - A Few Key Facts II-2
Bioabsorbable Stents Poised to Replace Drug-Eluting Stents in
Future II-2
Market Overview II-3
Current & Future Analysis II-3
Growth Drivers II-4
Restenosis - the Real Growth Driver II-4
Aging Population Propels Coronary Stents Market II-4
Limitations and Challenges Ahead II-4
Technological Challenges II-5
Safety- Efficacy Factor II-5
Regulatory Challenges II-5
Price Factor II-5
Threats to Coronary Stents - Alternative Therapies/Devices II-5
Cell Transplantation - A Threat to Coronary Stents II-6
Regulations for Conducting Clinical Trials Bioabsorbable
Stents in Select Regions II-6
The United States II-6
Europe II-6
Australia II-7
Competitive Scenario II-7
Focus on Select Bioabsorbable Stents II-7
Absorb® (Abbott Laboratories, US) II-7
ART Bioabsorbable Stent (Arterial Remodeling Technologies,
France) II-8
DREAMS (BIOTRONIK, Germany) II-8
DESolve™ Coronary Scaffold (Elixir Medical, US) II-8
IGAKI-TAMAI® (Kyoto Medical Planning, Japan) II-8
ReZolve® (REVA Medical Inc., US) II-9

2. PRODUCT OVERVIEW II-10
Coronary Artery Disease-A Perspective II-10
Treatment Options for Coronary Artery Disease II-10
Percutaneous Coronary Intervention (PCI) II-10
Coronary Stenting II-10
Types of Coronary Stents II-11
Bare Metal Stents (BMS) II-11
Drug Eluting Stents (DES) II-11
Bioabsorbable Stents II-12
Design and Composition of Bioabsorbable stents II-12
Different Types of Bioabsorbable Stents II-12
Metallic Bioabsorbable Stents II-12
Polymer Bioabsorbable Stents II-13
Degradation Period of Select Bioabsorbable Materials II-13
Advantages of Bioabsorbable stents II-13
Challenges II-14
Other Treatment Options for Coronary Heart Disease II-15
Coronary Artery Bypass Grafting (CABG) II-15
Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) II-15
TransMyocardial Laser Revascularization (TMR) II-15
Peripheral Arterial Disease: Understanding the Stealthy Peril II-15
Treatment for PAD II-16
Lifestyle Changes II-16
Medication II-16
Surgery II-17
Stenting- A Treatment Option for PAD II-17
Definition of Key Endpoints Used for Assessing Efficiency of
Stents II-18
MACE (Major Adverse Cardiac Events) II-18
Restenosis II-18
Stent Thrombosis II-18
Target Lesion Revascularization (TLR) II-19

3. PRODUCT LAUNCH/INTRODUCTION II-20
Abbott Laboratories Launches Absorb™ BVS in Europe and Other
Select Geographies II-20

4. RECENT INDUSTRY ACTIVITY II-21
Abbott Laboratories Initiates ABSORB III Clinical Trial in the US II-21
ART Conducts First-in-Human Implant of ART Bioabsorbable Stent II-21
Kyoto Medical Planning Releases Data to Demonstrate Efficacy
of IGAKI-TAMAI® Stent II-21
REVA Medical Receives Clearance to Conduct Clinical Trials for
ReZolve® in Brazil and Germany II-22
Xenogenics Acquires Ideal™ BioStent Assets from Investment Funds II-22
ART Discloses Data for ART Bioabsorbable Stent Platform II-23

5. FOCUS ON SELECT GLOBAL PLAYERS II-24
Abbott Laboratories (US) II-24
Amaranth Medical, Inc. (US) II-24
Arterial Remodeling Technologies SA (France) II-25
BIOTRONIK SE & Co. KG (Germany) II-25
Elixir Medical Corporation (US) II-25
Kyoto Medical Planning Co., Ltd. (Japan) II-26
REVA Medical, Inc. (US) II-26

6. GLOBAL MARKET PERSPECTIVE II-27
Table 1: World Current and Future Analysis for Bioabsorbable
Stents by Geographic Region - US, Europe, Asia-Pacific, and
Rest of World Markets Independently Analyzed with Annual Sales
in '000 Units for Years 2013 through 2018 (includes
corresponding Graph/Chart) II-27

Table 2: World 6-Year Perspective for Bioabsorbable Stents by
Geographic Region - Percentage Breakdown of Volume Sales for
US, Europe, Asia-Pacific, and Rest of World Markets for Years
2013 and 2018 (includes corresponding Graph/Chart) II-28

III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Market Overview III-1
Growth III-1
Coronary Artery Disease - A US Perspective III-1
Baby Boomers Boost Coronary Stent Market III-1
Challenges Ahead III-2
Current and Future Analysis III-2
Products in the Pipeline III-2
Competitive Scenario III-2
Strategic Corporate Developments III-2
Key Players III-3
B.Market Analytics III-5
Table 3: The US Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2018 (includes corresponding Graph/Chart) III-5

2. EUROPE III-6
A.Market Analysis III-6
Overview III-6
Growth Drivers III-6
Cardiovascular Disease in Europe - A Perspective III-6
Highly Diverse Europe III-6
Product Launch III-7
Strategic Corporate Developments III-7
Key Players III-9
B.Market Analytics III-10
Table 4: European Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2018 (includes corresponding Graph/Chart) III-10

3. ASIA-PACIFIC III-11
A.Market Analysis III-11
Overview III-11
A Few Key Facts III-11
Asia-Pacific - A Price Sensitive Market III-11
Growth drivers III-11
Current and Future Analysis III-12
A Regional Perspective III-12
Japan III-12
Prospects Weighed down by Regulatory Entanglements III-12
Japanese Coronary Stents Command Higher Prices III-12
Competitive Landscape III-12
China III-13
Healthcare Reforms to Propel Stent Market III-13
Strategic Corporate Development III-13
Kyoto Medical Planning Co., Ltd. - A Key Player III-13
B.Market Analytics III-14
Table 5: Asia-Pacific Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2018 (includes corresponding Graph/Chart) III-14

4. REST OF WORLD III-15
Market Analysis III-15
Table 6: Rest of World Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2018 (includes corresponding Graph/Chart) III-15

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 16 (including Divisions/Subsidiaries - 17)

The United States (9)
Japan (1)
Europe (4)
- France (1)
- Germany (2)
- The United Kingdom (1)
Asia-Pacific (Excluding Japan) (3)

To order this report:
: Global Bioabsorbable Stents Industry

__________________________
Contact Clare: [email protected]  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker